Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANRS 173 ALTAR phase III trial of induced triple therapy then dual nucleosides versus immediate dolutegravir + lamivudine in treatment-naive HIV-1 infection
2019-001961-34Phase 3Completed
- Sponsor
- ANRS
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dolutegravir, lamivudine, tenofovir and emtricitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by ANRS. Started May 2019; status: completed.
02
Drugs
dolutegravirlamivudinetenofoviremtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2019-001961-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001961-34.